Abionyx Pharma SA
PAR:ABNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abionyx Pharma SA
Depreciation & Amortization
Abionyx Pharma SA
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abionyx Pharma SA
PAR:ABNX
|
Depreciation & Amortization
-€158k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Depreciation & Amortization
-€4.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Depreciation & Amortization
-€50.9m
|
CAGR 3-Years
-225%
|
CAGR 5-Years
-101%
|
CAGR 10-Years
-59%
|
|
|
Inventiva SA
PAR:IVA
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Depreciation & Amortization
-$3.9m
|
CAGR 3-Years
35%
|
CAGR 5-Years
29%
|
CAGR 10-Years
-15%
|
|
|
Abivax SA
PAR:ABVX
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abionyx Pharma SA
Glance View
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
See Also
What is Abionyx Pharma SA's Depreciation & Amortization?
Depreciation & Amortization
-158k
EUR
Based on the financial report for Dec 31, 2025, Abionyx Pharma SA's Depreciation & Amortization amounts to -158k EUR.
What is Abionyx Pharma SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
-6%
Over the last year, the Depreciation & Amortization growth was -31%. The average annual Depreciation & Amortization growth rates for Abionyx Pharma SA have been -6% over the past three years .
